Patients Oriented Access Scheme: Learning From The Success Of The Israeli Innovative Solution For The Escalating Drugs Prices

OBJECTIVES: To show market results of implementing patients oriented access scheme (POAS) method based on balanced risk sharing that allows an efficient process for inclusion of newly introduced pharmaceuticals into the public package and dealing with market failures that unable all players to reach...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2017-10, Vol.20 (9), p.A690
Main Authors: Adijes-Toren, A, Brammli-Greenberg, S
Format: Article
Language:English
Subjects:
Agreements
Beneficiaries
Drug therapy
Drugs
Hepatitis C
Learning
Market shares
Patients
Prescription drugs
Prices
Pricing policies
Reimbursement
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVES: To show market results of implementing patients oriented access scheme (POAS) method based on balanced risk sharing that allows an efficient process for inclusion of newly introduced pharmaceuticals into the public package and dealing with market failures that unable all players to reach their goals. METHODS: An ongoing analysis of MoH database to examine the influence of the POAS on the inclusion of pharmaceuticals into the public package and number of beneficiaries. RESULTS: The POAS method creates more opportunities for medicines to be publicly funded with mutual risk sharing. The size of the budget for new drugs under agreements increased form 7.5 million NIS in 2011 to 156 million NIS in 2016 (accounted for more the 50% of the budget); the number of potential patients treated under POAS agreements increased from 150 in 2011 to 22.0CO in 2016. The most significant agreements were those which allowed Israel to be the one of the first countries which publicly funds the direct-acting antivarls (DAAs) indicated for the treatment of chronic hepatitis C (CHC) drugs. CONCLUSIONS: The method seems to successfully facilitate patient access to the newest treatment under the constraints of public budget available by promoting the achievement of the goals of the various players. This study creates an opportunity for cross-national learning to face the challenge of pharmaceuticals spending.
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2017.08.1754